BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB
The delisting is a result of the company's non-compliance with Nasdaq Listing Rule 5550(b)(1), pertaining to its minimum shareholder equity requirement.
BrainStorm has already secured approval for its common stock to be quoted on the OTCQB Venture Market, a U.S. trading platform operated by OTC Markets Group. The company anticipates its shares will begin trading on the OTCQB under the same symbol, BCLI, beginning at the open of trading on July 18, 2025, or as soon as possible thereafter.
Chaim Lebovits, CEO of BrainStorm Cell Therapeutics, stated, 'While this delisting from Nasdaq is a challenging outcome, we want to assure our shareholders and the patient community that it does not alter our core mission or our unwavering commitment to advancing NurOwn for ALS patients. Our pre-arranged transition to OTCQB ensures continuous trading for our shares and allows us to focus entirely on NurOwn's development. We remain fully dedicated to our ongoing scientific and clinical programs, including preparations for our pivotal Phase 3b trial under the Special Protocol Assessment (SPA) agreement with the FDA.'
The company confirms that the delisting does not impact its business operations, its ongoing research and development efforts, or its commitment to its shareholders. BrainStorm will continue to provide updates on its progress and financial status in compliance with applicable SEC regulations.
About NurOwn® The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.
About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.
NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the 'Floor Effect' – a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit www.brainstorm-cell.com.
Notice Regarding Forward-Looking Statements This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
CONTACTS
Investors:Michael Wood Phone: +1 646-597-6983 mwood@lifesciadvisors.com
Media:Uri Yablonka, Chief Business Officer Phone: +1 917-284-2911 uri@brainstorm-cell.com
Logo – https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-nasdaq-delisting-and-transition-to-otcqb-302508133.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Free Malaysia Today
6 hours ago
- Free Malaysia Today
US stocks hold steady after wholesale prices jump
Markets have been monitoring inflation in light of president Donald Trump's tariffs. (Reuters pic) NEW YORK : Wall Street stocks shook off early losses to finish essentially flat Thursday as markets digested disappointing inflation data that complicates expectations for lower Federal Reserve interest rates. The producer price index rose 0.9% on a month-on-month basis, much greater than analysts expected following benign consumer pricing data earlier this week. The Dow Jones Industrial Average finished down less than 0.1% at 44,911.26. The broad-based S&P 500 edged up less than 0.1% to 6,468.54, while the tech-rich Nasdaq Composite Index was virtually unchanged at 21,710.67. Markets have been monitoring inflation in light of president Donald Trump's tariffs, with Tuesday's consumer price report adding to confidence the Fed will lower rates in September. But after Thursday's report, a potential half-point interest rate cut is probably 'off the table', said Jack Ablin of Cresset Capital Management. The report 'suggests that companies are currently bearing the brunt of tariffs,' Ablin said. 'We would expect that companies will start to pass these costs along'. Among individual companies, Intel surged 7.4% following a Bloomberg News report that Trump is considering an investment in the beleaguered chip company in exchange for a government stake. Such a deal would represent Trump's latest departure from the US government's traditional laissez-faire posture towards business. Deere & Co sank 6.8% after it reported a drop in profits and lowered the ceiling of its full-year earnings range.
BusinessToday
3 days ago
- BusinessToday
Dow Hits Record High, Mixed Data Pressures Broader Market
Pic source: FX Empire The Dow Jones Industrial Average ended modestly higher on Aug 15 after touching a fresh intraday record, lifted by a sharp rally in UnitedHealth Group's shares, even as the S&P 500 and Nasdaq fell on mixed economic signals that clouded the Federal Reserve's (Fed) next policy move. Reuters reported that UnitedHealth jumped nearly 12%, its biggest one-day gain since March 2020, after Berkshire Hathaway disclosed a new stake in the health insurer, while Scion Asset Management also boosted its holdings. The surge helped the healthcare sector log its best weekly performance since October 2022. The Dow gained 34.86 points, or 0.08%, to close at 44,946.12. The S&P 500 slipped 0.29% to 6,449.80 and the Nasdaq Composite fell 0.40% to 21,622.98. For the week, the Dow rose 1.74%, the S&P 500 added 0.94% and the Nasdaq advanced 0.81%. The small-cap Russell 2000 outperformed with a 3.13% weekly gain. Markets remain focused on the Fed, with traders betting on a 25-basis-point rate cut in September following signs of labour market weakness and muted tariff-driven inflation. However, Chicago Fed President Austan Goolsbee urged caution, noting uneven economic data. July retail sales grew in line with forecasts, but factory output and consumer sentiment weakened under tariff pressures. Geopolitical developments also loomed large. Investors eyed a meeting between US President Donald Trump and Russian President Vladimir Putin in Alaska, seen as pivotal for Ukraine peace prospects and the outlook for crude oil prices. Trump also signalled new tariffs on steel and semiconductors could be unveiled next week. Trading volumes were lighter than average, with 16.3 billion shares changing hands across US exchanges versus a 20-session average of 18.2 billion.
The Star
3 days ago
- The Star
Dow ends higher, other indices slip on rate-cut uncertainty
The Dow rose 34.86 points, or 0.08%, to 44,946.12, the S&P 500 lost 18.74 points, or 0.29%, to 6,449.80 and the Nasdaq lost 87.69 points, or 0.40%, to 21,622.98. NEW YORK: The blue-chip Dow Jones ended higher after hitting an intraday record high on Friday, as UnitedHealth's shares jumped after Berkshire Hathaway raised its stake, but other Wall Street indices slipped as mixed data clouded the Federal Reserve's next monetary policy move. A meeting between US President Donald Trump and Russian counterpart Vladimir Putin was also on the radar, with markets hoping it could pave the way for a resolution to the Ukraine conflict and determine the outlook for crude prices. The two leaders began a meeting in Alaska on Friday afternoon.
